You are here

  • Home
  • Archive
  • Volume 30, Issue 2
  • Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Study of overall survival associated with nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis: a real-life comparison
  1. Ludovica Mazzoleni1,2,
  2. Cecilia Borsino1,
  3. Andrea Zovi1,2
  1. 1 UOC Farmacia, ASST Santi Paolo e Carlo, Milano, Italy
  2. 2 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Milano, Italy
  1. Correspondence to Dr Ludovica Mazzoleni, UOC Farmacia, ASST Santi Paolo e Carlo, Milano 20142, Italy; lmazzo2004{at}yahoo.it

https://doi.org/10.1136/ejhpharm-2021-003202

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Idiopathic pulmonary fibrosis (IPF) is a rare disease with a very debilitating course for which only limited therapeutic options are available. The incidence of IPF is increasing worldwide and in Italy ranges between 7.5 and 9.3 new cases per 100 000 per year.1 It is characterized by progressive and irreversible scarring of lung tissue resulting in a decline in respiratory function and usually a fatal outcome; survival of patients with IPF is usually less than 5 years from diagnosis.2 Currently, pharmacological treatments include only two active ingredients to delay disease progression: nintedanib, a tyrosine kinase inhibitor, and pirfenidone, a molecule with anti-inflammatory and antifibrotic activities. A retrospective analysis was conducted by hospital pharmacy staff at a …

    View Full Text

    Footnotes

    • Contributors Conceptualization: LM and AZ. Methodology: LM and CB. Investigation: LM and CB. Writing original draft: LM and AZ. Review and editing: AZ. Visualisation: CB and AZ.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.